News
JAGX
1.040
+4.51%
0.045
Weekly Report: what happened at JAGX last week (1118-1122)?
Weekly Report · 6d ago
Jaguar Health seeking partner to develop, commercialize NP300
TipRanks · 11/22 13:50
Weekly Report: what happened at JAGX last week (1111-1115)?
Weekly Report · 11/18 11:48
Jaguar Health Sees Revenue Growth with New Product Launches
TipRanks · 11/14 04:24
Jaguar Health Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/13 14:17
Jaguar Health reports Q3 EPS ($1.05) vs. ($22.50) last year
TipRanks · 11/13 14:10
Jaguar Health GAAP EPS of -$1.05, revenue of $3.11M
Seeking Alpha · 11/13 13:11
JAGUAR HEALTH INC: QTRLY REV $3.1 MLN
Reuters · 11/13 13:09
Exploring Jaguar Health's Earnings Expectations
Benzinga · 11/12 21:03
Weekly Report: what happened at JAGX last week (1104-1108)?
Weekly Report · 11/11 12:05
Jaguar Health Inc <JAGX.OQ> expected to post a loss of $2.37 a share - Earnings Preview
Reuters · 11/08 16:23
Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching
Barchart · 11/08 01:10
Jaguar Health announces FDA approval of renewal of Canalevia-CA1
TipRanks · 11/06 15:20
Jaguar Health to present crofelemer results at SABCS
TipRanks · 11/04 13:55
Weekly Report: what happened at JAGX last week (1028-1101)?
Weekly Report · 11/04 12:01
Weekly Report: what happened at JAGX last week (1021-1025)?
Weekly Report · 10/28 11:51
Weekly Report: what happened at JAGX last week (1014-1018)?
Weekly Report · 10/21 11:46
Jaguar Health launches Gelclair prescription product in the U.S.
TipRanks · 10/16 12:46
JAGUAR HEALTH: NAPO PHARMACEUTICALS INITIATED COMMERCIAL LAUNCH OF FDA-APPROVED ORAL MUCOSITIS PRESCRIPTION PRODUCT GELCLAIR IN U.S.
Reuters · 10/16 12:37
Weekly Report: what happened at JAGX last week (1007-1011)?
Weekly Report · 10/14 12:23
More
Webull provides a variety of real-time JAGX stock news. You can receive the latest news about Jaguar Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About JAGX
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.